Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02148796 · ClinicalTrials.gov registry record · Phase 2
Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness
A Phase 2 study, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 2
- Development phase
- 822
- Enrollment target
NCT02148796 is a Phase 2 study that has completed, run by University of Arizona. The registered enrollment target is 822 participants.
The verdict
NCT02148796, a Phase 2 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 822 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate if Broncho-Vaxom® given to high risk infants for 10 days, monthly, for two consecutive years can increase time to occurrence of the first episode of wheezing lower respiratory tract illness (WLRI) during a three year observation period off therapy.
Interventions
- OTHER Placebo
- DRUG Broncho-Vaxom (BV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 822 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2026-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02148796
The ClinicalTrials.gov registry entry for NCT02148796 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 822 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02148796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02148796 about?
NCT02148796 is a clinical study titled "Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness". The primary objective of this study is to evaluate if Broncho-Vaxom® given to high risk infants for 10 days, monthly, for two consecutive years can increase time to occurrence of the first episode of wheezing lower respiratory tract illness (WLRI) during a three year observation period off therapy.
What is the current status of trial NCT02148796?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 822 participants. The study started on 2017-01-01. Estimated completion is 2026-01-30.
What interventions are being tested in trial NCT02148796?
The interventions under investigation include: Placebo (OTHER), Broncho-Vaxom (BV) (DRUG).
Who is sponsoring clinical trial NCT02148796?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.